General Information of Drug (ID: DM6KXAU)

Drug Name
Dexpramipexole Drug Info
Synonyms
Dexpramipexole; 104632-28-2; (R)-PRAMIPEXOLE; (R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine; R-(+)-Pramipexole; (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; WI638GUS96; KNS-760704; (6R)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Dexpramipexole [USAN:INN]; UNII-WI638GUS96; (R)-Pramipexole;R-(+)-Pramipexole;KNS-760704; Dexpramipexole (USAN/INN); DEXPRAMIPEXOLE [INN]; SCHEMBL74780; DEXPRAMIPEXOLE [USAN]; MLS006011813; CHEMBL249420; DEXPRAMIPEXOLE [WHO-DD]; DTXSID50146624; FASDKYOPVNHBLU-SSDOTTSWSA-N; BCP12512; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6R)-; BDBM50568780; HY-17355B; AKOS005555111; CS-1196; DB15130; AC-36724; AS-56557; SMR004703492; D09886; EN300-123062; F19514; Q5268345; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; (R)-4,5,6,7-TETRAHYDRO-6-(PROPYLAMINO)-BENZOTHIAZOLE-2-AMINE; 2,6-BENZOTHIAZOLEDIAMINE, 4,5,6,7-TETRAHYDRO-N6-PROPYL-, (R)-
Indication
Disease Entry ICD 11 Status REF
Eosinophilic asthma CB02.0 Phase 3 [1]
Hypereosinophilic syndrome 2A20.3 Phase 2 [2]
Cross-matching ID
PubChem CID
59868
TTD Drug ID
DM6KXAU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug(s) Targeting Interleukin-4 (IL4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [4]
PEGylated pitrakinra DMBPJ9U Asthma CA23 Phase 2 [5]
Tepoxalin DMVS61L Asthma CA23 Phase 2 [6]
Romilkimab DMYEZ5J Idiopathic pulmonary fibrosis CB03.4 Phase 2 [7]
IL-4R DMYEGRH N. A. N. A. Phase 2 [8]
Pascolizumab DMU3XJP Asthma CA23 Phase 2 [5]
PF-07264660 DM0GI2H Atopic dermatitis EA80 Phase 1 [9]
PF-07275315 DMHRVUY Atopic dermatitis EA80 Phase 1 [9]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting Interleukin-13 (IL13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tralokinumab DM6ENSJ Atopic dermatitis EA80 Approved [10]
Lebrikizumab DMQP0X5 Severe asthma CA23 Phase 3 [5]
Cendakimab DM9LSBJ Eosinophilic esophagitis DA24.1 Phase 3 [11]
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [4]
PEGylated pitrakinra DMBPJ9U Asthma CA23 Phase 2 [5]
Romilkimab DMYEZ5J Idiopathic pulmonary fibrosis CB03.4 Phase 2 [7]
QAX-576 DMUWFI7 Allergic rhinitis CA08.0 Phase 2 [12]
Anrukinzumab DMTG2O0 Asthma CA23 Phase 2 [13]
Dectrekumab DM1H7UK Idiopathic pulmonary fibrosis CB03.4 Phase 2 [12]
CNTO-5825 DMF8WAT Allergic asthma CA23.0 Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Inhibitor [3]
Interleukin-4 (IL4) TTLGTKB IL4_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT05763121) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT02101138) An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome. U.S.National Institutes of Health.
3 Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
4 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
5 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
6 Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
7 A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
8 Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
9 Clinical pipeline report, company report or official report of Pfizer
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
12 Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
13 Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
14 Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.